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ABSTRACT

Background: Contrast-induced nephropathy (CIN) is associated with increased morbidity, and the need for short-term
hemodialysis. Although several preventive measures have been used, the best approach to prevent CIN is still controversial.
Objectives: This study is intended to evaluate the protective effect of carvedilol/ medium dose statin compared to the
recommended high dose atorvastatin on the development CIN in patients undergoing elective cardiac catheterization
(CC).
Patients and Methods: A total of 144 patients planned for CC were randomly assigned to:
• Group (A): 49 patients received atorvastatin as single high dose 80 mg 12 hours before CC and another 40 mg of
atorvastatin 2 hours before PCI.
• Group (B): 48 patients were prescribed carvedilol 12.5 mg twice daily for seven days before CC and continued for 24
hours post CC, plus 40 mg atorvastatin 12 hours before CC.
• Group (C): 47 patients received 40 mg atorvastatin 12 hours before CC.
Results: The baseline characteristics of the 3 groups were comparable. CIN incidence was the lowest in group A, but
was not significantly different (p=0.420). CIN developed in 4(8.2%), 6(12.2%), and 8(17%) patients in groups A, B, and
C respectively. Median change in CrCl 48 hours, and serum NGAL 4 hours post CC was significantly lower in group A
compared to group C (p=0.0330, p=0.0348 respectively).
Conclusion: The present study revealed that, combined carvedilol/statin regimen was comparable to single high dose
atorvastatin in CIN prevention. However, short high dose of atorvastatin might be preferable in terms of kidney function
preservation.
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CIN is defined as an increase in serum creatinine > 25%
or > 0.5 mg/dL above the baseline value after systemic
administration of iodinated contrast media following the
exclusion of other factors that may induce nephropathy,
such as nephrotoxins, hypotension, urinary obstruction,
or atheromatous emboli.[5] Serum creatinine rises after
48 hours, peaks in 3-5 days and returns to normal in 21
days, in the absence of other causes of renal failure.[6] This
might lead to dialysis, prolongation of hospitalization, and
increase in morbidity and mortality.[2]

INTRODUCTION
Diagnostic and invasive cardiac catheterization
(CC) have been widely used in myocardial infarction
(MI) patients.[1] Those patients are at increased risk of
complications related to contrast media (CM) usage during
CC procedure.[2] Contrast induced nephropathy (CIN),
is one of the complications and one of the major causes
behind hospital-acquired acute kidney injury.[3]
Pathogenesis of CIN is not clear but most studies
suggested that, vasoconstriction of renal vessels, oxidative
stress, free radical formation, and endothelial dysfunction
are thought to be the major causes.[4] Length and amount
of exposure to CM were found to be related to the degree
of renal tubular cell death.[3]

As serum creatinine rising in response to nephropathy
might be delayed and also GFR might fall at any time
within 3-5 days of CIN development,[7,8] recent studies
proved that, the biomarker neutrophil gelatinase-associated
lipocalin (NGAL) might be an alternative to creatinine in
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the early evaluation of acute kidney damage after exposure
to CM.[9, 10] NGAL sharply rises in blood and urine within 2
to 4 hours from kidney injury as a compensatory response
to defend against oxidative stress-mediated kidney toxicity,
which may lessen the degree of damage on ongoing insult
and mediate tissue protection.[7]

All patients who were scheduled for elective CC
were screened for eligibility to be included in the study.
Patients aged between 18 and 65 years with serum
creatinine ≤ 1.5 mg/dL, on moderate dose of atorvastatin
40 mg or equivalent, with moderate to high risk of CIN
(Mehran score ≥ 6)[19] were included. Patients were
excluded if they were suffering from ST-segment elevation
myocardial infraction (STEMI), and needed immediate
cardiac catheterization,[20] those with elevated liver
enzymes aspartate aminotransferase (AST), and alanine
aminotransferase (ALT) three times the upper limit of
normal),[15] or with active infection, patients allergic to
or have contraindication to contrast media, carvedilol,
or atorvastatin. Patients vitamins, minerals, or any
medication with antioxidant properties 7 days prior to CC,
hemodynamically unstable patients (defined as abnormal
or unstable blood pressure, especially hypotension (blood
pressure less than 90/60 mm Hg),[21] patients who required
dialysis, pregnancy, patients used carvedilol in the past
three months, or those who used nephrotoxic agent in the
past 48 hours or exposure to contrast agent in the past 7
days were also excluded.

The best approach to prevent or reverse CIN is still
controversial. The benefits of different strategies including
intravenous hydration either with isotonic saline or sodium
bicarbonate, statins, N- acetyl cysteine (NAC), iloprost,
alprostadil, prostaglandin, theophylline, ascorbic acid,
and tocopherol have been considered.[9] Despite all the
previously mentioned interventions, hydration either orally
or intravenously with isotonic saline is still believed to be
the most efficient treatment for prevention of CIN.[3] Statins
have proven efficacy to protect against CIN in patients at
risk for development of CIN after CM exposure.[11] The
reported significant decrease in CIN incidence among
patients using statins makes it a highly recommended
intervention in protection from CIN, especially short high
dose atorvastatin which was recommended by European
Society of Cardiology (ESC) for all patients with moderate
to high risk for CIN.[3,12] High doses statins were defined
as 20/40 mg rosuvastatin or 80 mg atorvastatin or 80 mg
simvastatin.[3]

All recruited patients were evaluated for the risk of
CIN using Mehran risk score.[22] All risk variables were
assessed and the score was at least 6 in all patients before
they were included in the study except for the variable of
volume of contrast media, whose points were added to the
risk score after the CC procedure.

Beta-blockers are one the of recommended medication
by the American Heart Association and American College
of Cardiology (AHA/ACC) and European Society of
Cardiology (ESC) in the treatment of ischemic heart
diseases even in patients who did not experience MI.[13,14]
Carvedilol a member of beta-blockers family was
found to have beneficial effect in CIN prevention.[15,16]
Theoretically, it has this potential effect to protect from
CIN due to its vasodilatory effect on renal blood vessels
and its antioxidant activity.[17]

2.2. Study design
In this randomized, prospective, parallel controlled
study, all recruited patients were randomly assigned to one
of three groups:
•
Group (A) included 49 patients who received high
dose statin (80 mg atorvastatin) 12 hours before CC and 40
mg just 2 hours before CC.[23]

Up-to-date, there is no study that evaluated the possible
reno-protective effect of combined beta-blocker with
statin prior to CC in comparison to short high dose statins.
Thus, the aim of this study is to compare the efficacy of
carvedilol combined with moderate dose statin to shortterm high dose atorvastatin in reducing the risk of CIN
after cardiac catheterization in patients with moderate to
high risk to CIN.

•
Group (B) included 48 patients who received
12.5 mg carvedilol twice daily for 7 days before CC and
continued for 24 hours after the CC, plus the moderate
dose (40 mg) atorvastatin 12 hours before the CC.[24]
•
Group (C) included 47 patients who received
moderate dose (40 mg) atorvastatin 12 hours before CC as
control group.
All recruited patients were hydrated with intravenous
(IV) 0.9% sodium chloride (NaCl) at a rate of 0.5-1
mL/kg/hour for 4-6 hours before and 4-6 hours after CC.[25]
The type of dye used for all study participants was nonionic
low-osmolar contrast dye (iopromide).

PATIENTS AND METHODS
A 2.1. Study population
This study was conducted in the National Heart Institute
(NHI), Giza, Egypt, during the period between February
2016 and May 2017. The study protocol was approved by
the Ethics Committee of the Faculty of Pharmacy, Cairo
University, and scientific committee of the NHI. The study
was conducted according to the Declaration of Helsinki
principles.[18] Written informed consent was obtained from
all the study participants (Clinicaltrials.gov Registration:
NCT03867994).

Relevant demographic data, comorbidities and
medication history were recorded for all study participants.
All the patients were screened for the following parameters
to determine the primary endpoint (CIN) and secondary
endpoints (kidney function and serum NGAL):
•
Serum creatinine (Cr) baseline (before initiating
the hydration) and 48 hours after the CC procedure to
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evaluate the incidence of CIN (defined as absolute rise in
the baseline serum creatinine concentration by 0.5 mg/dL
after 48 hours from CC).[26]

GraphPad Prism software (version 5.0; GraphPad Software,
Inc., San Diego, CA, United States). Numerical data were
presented as mean and standard deviation (SD) and median
and inter-quartile range (IQR), while categorical data were
described as frequency and percentage.[30] Chi-square test
was used for comparison of nominal variables. Quantitative
data were tested for normality using Shapiro-Wilk test.
If the data was normally distributed one-way ANOVA
followed by Tukey’s test were used for comparison.
For data that did not pass normality test Kruskal-Wallis
followed by Dunn’s test were used for comparisons.[30]
Univariate analysis was performed to predict if any of
study variables predicted CIN development.[31] Univariate
analysis was performed by using Student t-test for normally
distributed data or Mann-Whitney U test for data which
did not pass normality test and Chi-square test for nominal
variables.[31] For within group comparisons Wilcoxon test
was used.[31] Correlation between numerical variables was
tested by Spearman-rho method.[32] A p-value < 0.05 was
considered significant.[33]

•
Blood urea nitrogen (BUN) was measured before
and 48 hours post-CC.
•
Creatinine clearance (CrCl) was calculated
using Cockcroft–Gault equation[27] on admission, and recalculated 48 hours post CC using Cockcroft-Gault for all
patients except for patients who showed > 0.5 mg/dL rise
in SCR where Jelliffe and Jelliffe equation for unstable
kidney function was used.[28]
•
Serum NGAL baseline was measured before the
initiation of hydration, and 4 hours after CC procedure.
NGAL was assayed by enzyme-linked immunosorbent
assay ELISA (Glory Science Co., Ltd, CHINA).

3.Statistical analysis
G power software was used to determine sample size,
a minimum sample size of 34 patients in each group
was recommended according to literature based on the
incidence of CIN,[29] the power of the test was set at 0.8
and alpha of 0.05.

RESULTS
Out of 1800 screened patients, a total of 173 patients
were eligible and consented to take part in the study
(Figure 1).

Statistical analysis was carried out using IBM© SPSS©
Statistics version 22 (IBM© Corp., Armonk, NY, USA), and

Fig.1: Patients selection and recruitment flow diagram.
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between the three groups p=0.030 (Table 1). However,
univariate analysis for CIN development had been
performed and revealed that furosemide did not influence
the development of CIN (p=0.488).

The three groups were comparable with respect to
their demographic data, clinical baseline data, and all preoperative medication history except for the number of
patients on furosemide which was significantly different

Table 1: Demographic and clinical characteristics of the recruited patients in the three study groups
Parameter
Age (years), median (IQR)

∞

Group A N=49

Group B N=48

Group C N=47

P value

55.26±6.239

54.50±9.265

57.56±7.781

0.13

18(36.7)

28(58.3)

25(53.2)

0.08

89.24±18.15

89.25±16.20

93.06±18.08

0.47

167.1±8.202

165.8±8.277

Gender (Number of males (%))€
Average weight (kg) ± SD

¥

Average height (cm) ± SD

¥

Body mass index BMI (kg/m2), median (IQR)∞

31.51(27.83-35.05) 32.16(29.09-34.44)

Mehran score, median (IQR)

168.2±8.248

0.37

32.7(29.3-35.92)

0.46

7(7-9)

7(6-9)

8(6-9)

0.35

Number of hypertensive patients (%)¥

49(100)

48(100)

47(100)

1

Number of anemic patients (%)

14(28.6)

18(37.5)

8(17)

0.08

Number of diabetic patients (%)¥

41(83.7)

39(81.3)

31(66)

0.08

15(30.6)

15(31.3)

20(72.6)

0.5

∞

¥

Number of patients with heart failure class I and II (%)

¥

Number of patients with heart failure class III, and IV (%)

15(30.6)

9(18.8)

8(17)

0.22

Ejection fraction%, median (IQR)∞

37(75.5)

38(79.2)

32(68.1)

0.45

130(120-150)

130(120-150)

140) 130-150)

0.24

80(70-90)

80(70-90)

90(80-90)

0.33

Number of patients undergoing angiography only (%)

37(75.5)

38(79.2)

31(66)

0.32

Number of patients undergoing PCI (%)€

12(24.5)

10(20.8)

16(34)

0.32

¥

Systolic blood pressure (mmHg), median (IQR)

∞

Diastolic blood pressure (mmHg), median (IQR)∞
€

Volume of contrast media (mL), median (IQR)

80(70-110)

80(62.5-100)

100) 70-50)

0.42

Volume of fluid administered before CC (mL), median (IQR)∞

240(172-360)

240(160-360)

231(172.360)

0.80

Volume of fluid administered after CC (mL), median (IQR)∞

240(160-360)

231(172.5-360)

240(172-360)

0.79

∞

Patient medication history
Number of patients on antiplatelets (%)€

48(100)

48(98)

47(100)

0.38

Number of patients on oral nitrates (%)€

45(91.8)

43(89.6)

43(91.5)

0.92

Number of patients on trimitazidine (%)

21(42.9)

24(50)

23(48.9)

0.75

Number of patients on statins (%)€

49(100)

48(100)

47(100)

1

Number of patients on ACEIs (%)

38(77.6)

37(77.1)

33(70.2)

0.65

Number of patients on ARBs (%)€

3(6.1)

2(4.2)

5(10.6)

0.45

5(10.2)

10(20.8)

3(6.4)

0.09

14(28.6)

20(41.7)

8(17)

0.030*

Number of patients on spironolactone (%)

8(16.3)

12(25.5)

17(35.4)

0.1

Number of patients on anti-diabetics (%)

41(83.1)

39(81.3)

31(66)

0.08

Number of patients on bisprolol (%)€

14(28.6)

7(14.9)

0.11

€

€

Number of patients on CCBs (%)

€

Number of patients on furosemide (%)

€
€

€

Data are presented as mean ± standard deviation, median, and interquartile range [25th–75th percentile], frequency and percent.
*P-values <0.05 were considered significant.
Anemia defined as hemoglobin <13g/dL for men and <12g/dL for women.[39]
Heart failure are classified according to New York Heart Association.[24]
ACEIs: angiotensin converting enzyme inhibitor.
ARBs: angiotensin receptor blockers.
CCBs: calcium channel blocker.
Type of statistical test: ∞ Kruskal-Wallis test followed by Dunn’s test, € Chi-square test, ¥ one-way ANOVA followed by Tukey’s.
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serum NGAL was comparable between the three groups.
At 4 hours post CC, group B had significantly lower level
(23.7 µg/L) of serum NGAL when compared to group
C (38.17 µg/L). However, the median change in serum
NGAL, showed the least rise in the group receiving high
dose atorvastatin (3.6499 µg/L) in comparison group C
(10.60 µg/L) (Table 2, Figure 2).

Both the incidence of CIN and median of SCr elevation
were not significantly different between the three groups
(p > 0.05). Although the three groups were comparable
with respect to CrCl at baseline, and 48 hours post
intervention. The median change in CrCl was significantly
lower in the group A which showed the lowest decline in
kidney function (median change: -6.8 mL/min) compared
to the group C (median change: -15.6 mL/min). Baseline

Table 2: Renal biochemical and clinical parameters for recruited patients in the three groups during the study period
Group A N=49

Group B N=48

Group C N=47

P value

4 (8.2%)

6 (12.2%)

8 (17%)

0.42

SCr on admission (mg/dL), median (IQR)∞

1(0.7-1.25)

0.9(0.6-1.2)

0.8(0.67-1)

0.23

SCr after 48 hours (mg/dL), median (IQR)∞

1.2(0.9-1.4)

1.05(0.8-1.375)

1.1(0.9-1.36)

0.64

The median change in SCr (mg/dL), (IQR)∞

0.2(0.1-0.3)

0.175(0.1-0.3)

0.3) 0.1-0.4)

0.15

67.9(49.9-90.5)

73.05(59.58-95.38)

80.3(57.5-109.1)

0.12

e-GFR (mL/min) 48 hours post procedure, median (IQR)∞

67.9(41.7 -80.70)

64.2(50.33-77.98)

64.5(51.7-93.5)

0.65

The median change in e-GFR (mL/min), (IQR)∞

-6.8)-13.50-0.2)

-7.15(-17.88- -0.55)

-15.6(-26.30- -3.4)†

0.03*

Serum NGAL on admission (µg/L), median (IQR)∞

26.65(14.58-41.55)

17.53(10.03-27.36)

29.23(10.94-48.09)

0.06

Serum NGAL after 4 hours (µg/L), median (IQR)∞

31.24(13.44-46.56)

23.7(15.83-45.25)

38.17(26.81-65.73)$

0.03*

The median change in serum NGAL (µg/L), (IQR)∞

3.86(-4.647-10.94)

7.979(0.4469-13.73)

10.01(0.78-23.02)†

0.04*

32(24.5-42.5)

30(24.25-38.25)

28(23.25-40.25)

0.46

37(30-46)

37(29.25-45)

36.35(27.75-45.75)

0.844

5(-4-12)

5(2.25-12.75)

5(-1.250-10)

0.69

Patients who developed CIN N (%)€

e-GFR (mL/min) on admission, median (IQR)∞

BUN (mg/dL) on admission, median (IQR)∞
BUN (mg/dL) 48 hours post procedure, median (IQR)∞
The median change in BUN (mg/dl), (IQR)∞

Data presented as frequency and percent or median and interquartile range [25th–75th percentile], *P-values <0.05 were considered significant.
CIN: contrast induce nephropathy, NGAL: neutrophil gelatinous associated lipocaline, SCr: serum creatinine, e-GFR: estimated glomerular
filtration rate, BUN: blood urea nitrogen.
† Control group is significantly different from atorvastatin group.
$ Control group is significantly different from carvedilol group.
Type of statistical test: ∞Kruskal-Wallis test, € Chi
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Fig. 2: Comparison of kidney function markers (A) SCr (B) Crcl (D) BUN, and (C) NGAL as acute kidney injury marker within each group
before and after CC using the median values and Wilcoxon test, *P<0.05 was considered significant. A: Serum creatinine before and after
CC in each group, B: Creatinine clearance before and after CC in each group, C: Serum NGAL before and after CC in each group and D:
Blood urea nitrogen before and after CC in each group. CC: cardiac catheterization; Scr: serum creatinine, Crcl: creatinine clearance, NGAL:
neutrophil gelatinous associated lipocaline ,BUN: blood urea nitrogen.

DISCUSSION
There was no significant difference in the incidence
of CIN among the three groups. The definition used
to describe CIN in this study was a 0.5 mg/dL absolute
increase in serum creatinine,[3] since it was better correlated
to mortality rate after 6 months.[26]

had anemia, all patients had hypertension. On the basis of
the risk score introduce by Mehran et al.,[22] the incidence
of CIN development in patients with medium to high risk
ranged between 14.1 and 26.1%.
The present study reported that, 7 preoperative days
of carvedilol combined with moderate dose atorvastatin
showed comparable results to short-term high dose
of atorvastatin in the primary outcome which was the
protection against CIN development. Otherwise, shortterm high dose atorvastatin regimen was superior over
conventional moderate dose atorvastatin in other outcomes
as preserving CrCl 48 hours post CC and preventing serum
NGAL rising 4 hours post CM exposure.

Wide ranges of CIN incidence had been reported, from
7% in patients with low or no risk for CIN development to
reach 25% in patients with high risk for CIN.[34] The overall
incidence of CIN development in the present study was
12.5%, which is considered relatively high incidence. This
can be attributed to the high risk profile of the recruited
patients: 77% of the patients had diabetes mellitus,
83(57.6%) patients had heart failure, 40(27.7%) patients
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Statins have a proven efficacy to protect against CIN
regardless of LDL cholesterol level of the patients,[11,12] and
therefore, are considered one of the main CIN preventative
measures according to the European Society of Cardiology
CIN prevention guidelines.[3]

regimen with IV 0.9% NaCl towards CIN prevention or
even inhibiting serum creatinine peak rise two and five
days post CM exposure.[43] Also, carvedilol and nebivolol
had proven to be superior to metoprolol in the prevention
of CIN.[15,45] However, the overall effect of nebivolol
towards CIN prevention in humans was not found to be
statistically significant when discussed in a meta-analysis
by Thamcharoen.[42] The meta-ananlysis evaluated
three clinical trials, and it reported that, pre-procedure
administration of nebivolol was not superior over control
group. Same incidence of CIN was reported when nebivolol
was compared to carvedilol and metoprolol. also, it was
reported that, nebivolol was superior over metoprolol in
reducing incidence of CIN.

A meta-analysis by Su et al, analyzed 150 clinical
trials evaluating 12 different interventions, comparing
their protective effect against the development of CIN. The
interventions included all of the following medications
in combination with hydration: N-acetylcysteine (NAC),
theophylline (aminophylline), fenoldopam, iloprost,
alprostadil, prostaglandin E1, statins, statins plus NAC,
bicarbonate sodium, bicarbonate sodium plus NAC,
ascorbic acid (vitamin C), tocopherol (vitamin E), a-lipoic
acid, atrial natriuretic peptide, B-type natriuretic peptide,
and carperitide. The meta-analysis revealed that, high-dose
statins plus hydration with or without NAC was the most
preferable strategy to prevent CIN in patients undergoing
CC[35].

Carvedilol defensive properties over different condition
affecting the kidney is well-recognized.[15,16,46] Yasar et al.,
proved that, carvedilol possessed reno-protective effect
in ureteral obstruction in rats by preventing oxidative
stress induced by obstruction ischemia.[47] Another study
by Akindele et al., showed the same reno-protective
effect of carvedilol in preventing nephrotoxicity mediated
by oxidative stress of doxorubicin.[46] In addition to its
antioxidant properties, nitric oxide (NO) releasing play a
major role in reno-protective effect of carvedilol.[48]

Fan et al., concluded in their meta-analysis on 19 clinical
trials that, all statins showed the same incidence of reducing
CIN.[36] Another meta-analysis by Liu et al., analyzed nine
randomized clinical trials showed that, patients using high
dose (80 mg) atorvastatin had significantly lower incidence
of CIN after coronary angiography.[37] Even a single high
loading dose of atorvastatin administered within 24 hours
prior CM exposure have proven its effect in reducing the
rate of CIN.[38]

Ozaydin et al.,[16] observed that, carvedilol synergized
the beneficial effect of NAC in preventing AKI that resulted
from oxidative stress and inflammation occurring during
cardiac surgery in humans, in addition to the decreased
incidence of CIN and peak serum creatinine rising after 5
days of procedure. Also, human trials showed promising
results of carvedilol in the prevention of CIN,[15,16] and this
was confirmed by the results of the present study.

The results of the present study are also in line with the
results of a multicenter study which evaluated 625 patients
on chronic statins undergoing CABG. Patients were
divided into two groups; one group was on regular statin
therapy while the other one withheld statins 24 hours prior
to CABG. Their results revealed that, preoperative statins
had the ability to prevent kidney injury evidenced by the
ability to inhibit plasma NGAL, and also other biomarkers
of AKI as urine IL-8, urine NGAL, and urine KIM-1.[39]

The combination therapy of carvedilol and atorvastatin,
which is widely used in patients with ischemic heart disease
who are suspected to undergo CC, was proven to decrease
mortality rate after MI, and after abdominal aortic aneurism
surgery.[49] One study had evaluated the combination of
carvedilol and atorvastatin in the protection of cyclosporine
induced nephrotoxicity in animals, and revealed that, the
combination reduced the nephrotoxicity of chronic use of
cyclosporine and preserve kidney function when compared
to each of them alone.[50]

Beta-blockers are among the most commonly
prescribed anti-ischemic medication classes in coronary
artery diseases specially prior to CC.[26,40] Several studies
proved the nephroprotective effect of beta-blockers
against oxidative stress mediated by CM in human and
animal models of CI-AKI.[15,40,41] Carvedilol, metoprolol,
and nebivolol were the most studied beta-blockers in the
prevention of CIN.[42, 43]

In the present study, the combination of carvedilol
to moderate dose atorvastatin showed comparable result
to single high dose atorvastatin the prevention of CIN
development, which could suggest the beneficial effect of
the combination.

Although metoprolol is still one of the most commonly
prescribed beta-blockers by physicians,[43] it does not
possess vasodilatory properties like carvedilol and
nebivolol.[44] In randomized controlled trials, metoprolol
did not prove to add any value over standard hydration
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CONCLUSION
The incidence of CIN was not significantly different
between carvedilol combined with moderate dose statin and
single high dose atorvastatin, suggesting the non-inferiority
of combined carvedilol/moderate dose atorvastatin to
high dose atorvastatin in CIN protection. However, only
short high dose of atorvastatin was found to be superior
to moderate dose atorvastatin in terms of kidney function
preservation by having the lowest decrease in CrCl, and
unaltered serum NGAL level after exposure to CM.

STUDY LIMITATIONS
Some of included patients were not naïve beta-blocker
which is considered as one of our study limitations, although
they were on beta-blocker but they were on bisprolol
and there is no evidence in the literature supporting the
protective effect of bisprolol against CIN development.
Although measuring serum NGAL 4 hours post CC is
a reliable test to estimation degree of the ongoing kidney
insult, it was recommended to measure it at other time
points as 12 hours and 24 hours after CC for confirmation.
This was difficult to achieve due to the nature of the study
which was self-funded. For the same reason investigators
were unable assess kidney injury acute biomarker such as
KIM-1, IL-18 to confirm the results.

RECOMMENDATIONS

3.

Rear R, Bell RM, Hausenloy DJ. Contrast-induced
nephropathy following angiography and cardiac
interventions.
Heart.
2016;102(8):638-648.
doi:10.1136/heartjnl-2014-306962

4.

Heyman SN, Reichman J, Brezis M. Pathophysiology
of radiocontrast nephropathy: A role for medullary
hypoxia. Invest Radiol. 1999;34(11):685.

5.

Mohammed NA, Rafie I, Mahfouz A, Achkar K,
Hajar R. Contrast-induced nephropathy. Hear Views.
2013;14(3):106. doi:10.4103/1995-705X.125926

6.

Sv P, Jayakumar KP, Jayaprakash VL, et al. Contrast
induced nephropathy a study of 850 patients undergoing
cardiac catheterization laboratory procedures. Kerala
Hear J. 2011;1:14-17.

7.

De Geus HRH, Betjes MG, Bakker J. Biomarkers
for the prediction of acute kidney injury: A narrative
review on current status and future challenges. Clin
Kidney J. 2012;5(2):102-108. doi:10.1093/ckj/sfs008

8.

Mohammed NMA, Mahfouz A, Achkar K,
et al. Contrast-induced Nephropathy. Heart Views.
2013;14(3):106-116. doi:10.4103/1995-705X.125926

9.

Benzer M, Alpay H, Baykan Ö, et al. Serum NGAL,
cystatin C and urinary NAG measurements for early
diagnosis of contrast-induced nephropathy in children.
Ren Fail. 2016;38(1):27-34. doi:10.3109/088602
2X.2015.1106846

Further trials on larger sample size might confirm
the protective effect of carvedilol against CIN and
the best regimen to be used before CC. In addition, a
longer observation period will allow long-term outcome
assessment.

10. Tong J, Li H, Zhang H, et al. Neutrophil gelatinaseassociated lipocalin in the prediction of contrastinduced nephropathy : A Systemic Review and Metaanalysis. Cardiovasc Pharmacol. 2015;66(3):239-245.

If beta-blockers are recommended before CC, carvedilol
in a dose of 12.5 mg given twice daily for 7 days before CC
might add a clinical value in the prevention of CIN.

11. Barbieri L, Verdoia M, Schaffer A, et al. The role
of statins in the prevention of contrast induced
nephropathy : a meta-analysis of 8 randomized
trials. J Thromb Thrombolysis. 2014;38(4):493-502.
doi:10.1007/s11239-014-1076-3

CONFLICT OF INTEREST

12. Singh N, Lee JZ, Huang JJ, et al. Benefit of statin
pretreatment in prevention of contrast-induced
nephropathy in different adult patient population:
Systematic review and meta-analysis. Open Hear.
2014;1(1):1-12. doi:10.1136/openhrt-2014-000127

There are no conflicts of interest.

REFERENCES
1.

2.

Slicker K, Lane WG, Oyetayo OO, et al. Daily cardiac
catheterization procedural volume and complications
at an academic medical center. Cardiovasc Diagn Ther.
2016;6(5):446-452. doi:10.21037/cdt.2016.05.02

13. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/
ACCF secondary prevention and risk reduction
therapy for patients with coronary and other
atherosclerotic vascular disease: 2011 update: A
guideline from the American Heart Association
and American College of Cardiology Foundation.
Circulation. 2011;124(22):2458-2473. doi:10.1161/
CIR.0b013e318235eb4d

Bartholomew BA, Harjai KJ, Dukkipati S, et al.
Impact of nephropathy after percutaneous coronary
intervention and a method for risk stratification. Am
J Cardiol. 2004;93(12):1515-1519. doi:10.1016/j.
amjcard.2004.03.008

8

EL-Gazar et al.

14. Cardiol RJ. 2013 ESC guidelines on the management
of stable coronary artery disease: The task force on
the management of stable coronary artery disease of
the European Society of Cardiology. Russ J Cardiol.
2014;111(7):7-79. doi:10.1016/j.rec.2013.11.008

24. Akgüllü Ç, Eryılmaz U, Huyut A, Al E. Comparison
of Carvedilol, Nebivolol and Metoprolol for the
Prevention of Contrast Induced Nephropathy. J Am
Coll Cardiol. 2013;62(18):223-224. doi:10.1016/j.
jacc.2013.08.634

15. Yilmaz M, Aydinalp A, Okyay K, et al. Comparison
of carvedilol and metoprolol for preventing
contrast-induced
nephropathy
after
coronary
angiography. CardioRenal Med. 2015;5(3):199-207.
doi:10.1159/000381964

25. Maioli M, Toso A, Leoncini M. Effects of hydration
in contrast-induced acute kidney injury after primary
angioplasty a randomized, controlled trial. Circ
Cardiovasc Interv. 2011;4:456-462. doi:10.1161/
CIRCINTERVENTIONS.111.961391

16. Ozaydin M, Peker T, Akcay S, et al. Addition of
N-acetyl cysteine to carvedilol decreases the incidence
of acute renal injury after cardiac surgery. Clin Cardiol.
2014;37(2):108-114. doi:10.1002/clc.22227

26. Guillon B, Ecarnot F, Marcucci C, et al. Incidence,
predictors, and impact on six-month mortality of
three different definitions of contrast-induced acute
kidney injury after coronary angiography. Am
J Cardiol. 2018;121(7):818-824. doi:10.1016/J.
AMJCARD.2017.12.029

17. Dulin B, Abraham WT. Pharmacology of carvedilol.
Am J Cardiol. 2004;93(9):3-6. doi:10.1016/j.
amjcard.2004.01.003

27. Michels WM, Grootendorst DC, Verduijn M, Elliott
EG, Dekker FW, Krediet RT. Performance of the
Cockcroft-Gault, MDRD, and new CKD-EPI
formulas in relation to GFR, age, and body size. Clin J
Am Soc Nephrol. 2010;5(6):1003-1009. doi:10.2215/
CJN.06870909

18. Helsinki. World Medical Association Declaration
of Helsinki. JAMA. 2013;310(20):2191-2194.
doi:10.1001/jama.2013.281053
19. Sgura FA, Bertelli L, Monopoli D, et al. Mehran
contrast-induced nephropathy risk score predicts
short- and long-term clinical outcomes in patients
with ST-elevation-myocardial infarction. Circ
Cardiovasc Interv. 2010;3(5):491-498. doi:10.1161/
CIRCINTERVENTIONS.110.955310

28. Jelliffe RW. Creatinine clearance: Bedside estimate.
Ann Intern Med. 1973;79(4):604. doi:10.7326/00034819-79-4-604
29. Patti G, Nusca A, Chello M, et al. Usefulness of
Statin Pretreatment to Prevent Contrast-Induced
Nephropathy and to Improve Long-Term Outcome
in Patients Undergoing Percutaneous Coronary
Intervention. Am J Cardiol. 2008;101(3):279-285.
doi:10.1016/j.amjcard.2007.08.030

20. Terkelsen CJ, Jensen LO, Tilsted HH, et al.
Primary percutaneous coronary intervention as a
national reperfusion strategy in patients with STsegment elevation myocardial infarction. Circ
Cardiovasc Interv. 2011;4(6):570-576. doi:10.1161/
CIRCINTERVENTIONS.111.962787

30. Motulsky
H.
Intuitive
Biostatistics :
A
Nonmathematical Guide to Statistical Thinking. (ed3).
Oxford University Press; 2014.

21. Freeman R, Wieling W, Axelrod FB, et al. Consensus
statement on the definition of orthostatic hypotension,
neurally mediated syncope and the postural tachycardia
syndrome. Clin Auton Res. 2011;21(2):69-72.
doi:10.1007/s10286-011-0119-5

31. Marusteri M, Bacarea V. Comparing groups for
statistical differences: how to choose the right
statistical test? Biochem Medica. 2010;20(1):15-32.
doi:10.11613/BM.2010.004

22. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk
score for prediction of contrast-induced nephropathy
after percutaneous coronary intervention. J Am
Coll Cardiol. 2004;44(7):1393-1399. doi:10.1016/j.
jacc.2004.06.068

32. Mukaka MM. Statistics corner: A guide to appropriate
use of correlation coefficient in medical research.
Malawi Med J. 2012;24(3):69-71.
33. Greenland S, Senn SJ, Rothman KJ, et al. Statistical
tests, P values, confidence intervals, and power:
a guide to misinterpretations. Eur J Epidemiol.
2016;31(4):337-350. doi:10.1007/s10654-016-0149-3

23. Galal H, Nammas W, Samir A. Impact of high dose
versus low dose atorvastatin on contrast induced
nephropathy in diabetic patients with acute coronary
syndrome undergoing early percutaneous coronary
intervention. Egypt Hear J. 2015;67(4):329-336.
doi:10.1016/j.ehj.2014.12.002

34. Azzalini L, Spagnoli V, Ly HQ. Contrast-Induced
Nephropathy: From Pathophysiology to Preventive

9

CARVEDILOL AND ATORVASTATIN FOR CIN PREVENTION

43. Akgüllü Ç, Eryılmaz U, Güngör H, et al. A clinical
study about contrast nephropathy: Risk factors and
the role of beta blockers. Anadolu Kardiyol Derg.
2015;15(3):232-240. doi:10.5152/akd.2014.5304

Strategies. Can J Cardiol. 2016;32(2):247-255.
doi:10.1016/j.cjca.2015.05.013
35. Su X, Xie X, Liu L, et al. Comparative Effectiveness
of 12 Treatment Strategies for Preventing ContrastInduced Acute Kidney Injury: A Systematic Review and
Bayesian Network Meta-analysis. Am J Kidney Dis.
2017;69(1):69-77. doi:10.1053/j.ajkd.2016.07.033

44. Fares H, Lavie CJ, Ventura HO. Vasodilating versus
first-generation β-blockers for cardiovascular
protection. Postgrad Med. 2012;124(2):7-15.
doi:10.3810/pgm.2012.03.2532

36. Fan J, Sun H, Zhao X. Statins for prevention
of contrast induced nephropathy after coronary
angiography: A network meta-analysis. Int J Clin Exp
Med. 2015;9(1):156-163.

45. Avci E, Yesil M, Bayata S, et al. The role of nebivolol
in the prevention of contrast-induced nephropathy in
patients with renal dysfunction. Anadolu Kardiyol
Dergisi/The Anatol J Cardiol. 2011;11:613-617.
doi:10.5152/akd.2011.164

37. Liu L-Y, Liu Y, Wu M-Y, et al. Efficacy of atorvastatin
on the prevention of contrast-induced acute kidney
injury: a meta-analysis. Drug Des Devel Ther.
2018;12:437-444.
https://www.dovepress.com/
efficacy-of-atorvastatin-on-the-prevention-ofcontrast-induced-acute-k-peer-reviewed-articleDDDT. Accessed July 15, 2018.

46. Akindele AJ, Oludadepo GO, Amagon KI, Singh D,
Osiagwu DD. Protective effect of carvedilol alone and
coadministered with diltiazem and prednisolone on
doxorubicin and 5-fluorouracil-induced hepatotoxicity
and nephrotoxicity in rats. Pharmacol Res Perspect.
2018;6(1). doi:10.1002/prp2.381

38. Quintavalle C, Fiore D, De Micco F, et al. Impact of a
high loading dose of atorvastatin on contrast-induced
acute kidney injury. Circulation. 2012;126(25):30083016. doi:10.1161/CIRCULATIONAHA.112.103317

47. Yasar A, Erdemir F, Parlaktas BS, et al. The effect
of carvedilol on serum and tissue oxidative stress
parameters in partial ureteral obstruction induced
rat model. Kaohsiung J Med Sci. 2013;29(1):19-25.
doi:10.1016/j.kjms.2012.08.003

39. Molnar A, Parikh C, Coca S, et al. Association
between preoperative statin use and acute kidney
injury biomarkers in cardiac surgical procedures. Ann
Thorac Surg. 2014;97(6):2081-2087. doi:10.1016/j.
athoracsur.2014.02.033.Association

48. Atwa A, Hegazy R, Shaffie N, Yassin N, Kenawy
S. Protective effects of vasodilatory Βeta-blockers
carvedilol and nebivolol against glycerol model of
rhabdomyolysis-induced acute renal failure in rats.
Maced J Med Sci. 2016;4(3):329-341. doi:10.3889/
oamjms.2016.082

40. Akgüllü Ç, Hekim T, Eryılmaz U, et al. The usefulness
of carvedilol and nebivolol in preventing contrast
nephropathy in rats The usefulness of carvedilol and
nebivolol in preventing contrast nephropathy in rats.
Ren Fail. 2015;37(3):511-517. doi:10.3109/088602
2X.2015.1006087
41. Coats A, Jain S. Protective effects of nebivolol from
oxidative stress to prevent hypertension-related target
organ damage. J Hum Hypertens. 2017;31(6):376381. doi:10.1038/jhh.2017.8

49. Kertai MD, Boersma E, Westerhout CM, et al.
A combination of satins and beta-blockers is
independently associated with a reduction in the
incidence of perioperative mortality and nonfatal
myocardial infarction in patients undergoing
abdominal aortic aneurysm surgery. Eur J Vasc
Endovasc Surg. 2004;28(4):343-352. doi:10.1016/j.
ejvs.2004.07.008

42. Thamcharoen N, Thongprayoon C, Edmonds P, et al.
Periprocedural nebivolol for the prevention of contrastinduced acute kidney injury: A systematic review and
meta-analysis. N Am J Med Sci. 2015;7(10):446.
doi:10.4103/1947-2714.168670

50. Gludağ S, Sbinç TB, Tali P, Ekyay ST, Cutlugon
TA. Effects of Atorvastatin and Carvedilol on
Chronic Cyclosporine Nephrotoxicity in Rats. J
Clin Exp Nephrol. 2018;3(1):1. doi:10.21767/24725056.100052

10

